AAD Virtual Meeting Experience 2020 Conference Review - reviewed by Dr. Saxon D Smith

In this review:

Oral JAK 1/JAK 2 inhibitor CTP-543 in alopecia areata
ARQ-151 improves chronic plaque psoriasis
Pityriasis rubra pilaris treated with ixekizumab
Risankizumab vs secukinumab in moderate-to-severe psoriasis
High concentration trichloro-acetic acid in skin photo-type IV-VI
Abrocitinib in moderate-to-severe atopic dermatitis
Omalizumab for cancer therapyassociated dermatologic adverse events
Impact of biologics on cancer survival in psoriasis patients
Evolution of skin microbiome from birth to 10 years
Lebrikizumab improves QOL in moderate-to-severe atopic dermatitis
Tralokinumab + topical corticosteroids in moderate-to-severe atopic dermatitis
Difelikefalin in chronic kidney disease patients with moderate-to-severe pruritus

Please login below to download this issue (PDF)